Protocol to rapidly screen CRISPR-Cas9 gene editing outcomes in a cell population by mutating eGFP to a blue or non-fluorescent phenotype
When designing genome editing therapy, it is crucial to measure outcomes of DNA damage repair. Here, we present a protocol to distinguish the outcome of targeted DNA damage repair from the bottom up, through a previously established readout of enhanced green fluorescent protein (eGFP) to blue fluorescent protein (BFP) mutations. We describe steps for producing eGFP-positive cells and differentiating between non-homologous end joining-induced gene knockout and homology-directed repair-induced-directed mutation in these cells. This protocol has potential for high-throughput and scalable assessment of gene editing techniques. For complete details on the use and execution of this protocol, please refer to Walther et al.<sup>1</sup> and Wilbie et al.<sup>2</sup>.
Authors
- Enrico Mastrobattista (ORCID: https://orcid.org/0000-0002-6745-2015)
- Danny Wilbie (ORCID: https://orcid.org/0000-0003-1004-304X)
- Olivier G. de Jong (ORCID: https://orcid.org/0000-0002-5952-9617)
Institutions
- Utrecht University (NL)
- Pharmo Institute (NL)
Publication Details
- Journal
- STAR Protocols
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1016/j.xpro.2025.103950
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek